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Abstract
Introduction: Little is known about the distribution of asthma severity in men and women in the general population. The
objective of our study was to describe asthma severity and change in severity according to gender in a cohort of adult asthmatics
Methods: Subjects with asthma were identified from random samples of the 22 to 44 year-olds from the general population,
screened for asthma from 1991 to 1993 in 48 centers from 22 countries and followed-up during 1998–2002, as part of the
European Community Respiratory Health Survey (ECRHS). All participants to follow-up with current asthma at baseline were
eligible for the analysis. To assess change over the follow-up, asthma severity at the two surveys was defined using
standardized data on respiratory symptoms, lung function and medication according to the Global Initiative for Asthma
(GINA) Guidelines. Another quantitative score (Ronchetti) further considering hospitalizations was also analysed.
Results: The study included 685 subjects with asthmafollowed-up over a mean period of 8.65 yr (min 4.3-max 11.7). At baseline,
asthma severity according to GINA was distributed as intermittent: 40.7%, 31.7% as mild persistent, 14% as moderate persistent,
and 13.5%as severe persistent. Using the Ronchetti score derived classification,the distribution ofasthmaseverity was 58% mild,
(intermittent and mild persistent), 25.8% moderate, and 15.4% severe. Whatever the classification, there was no significant
difference in the severity distribution between men and women. There was also no gender difference in the severity distribution
amongincidentcaseswhichdevelopedasthmabetweenthetwosurveys.Menwithmoderate-to-severeasthmaatbaselinewere
more likely than women to have moderate-to-severe asthma at follow-up. Using GINA, 69.2% of men vs. 53.1% of women
(p=0.09)withmoderate-to-severeasthmaatbaselinewere stillmoderate-to-severeatfollow-up. UsingRonchettiscore, 53.3% of
men vs. 36.2% of women (p=0.03) with moderate-to-severe asthma at baseline were still moderate-to-severe at follow-up.
Conclusions: There was no gender difference in asthma severity at the two surveys. However, our findings suggest that
asthma severity might be less stable in women than in men.
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Introduction
Several studies have reported a higher severity of asthma in
women than in men, both in the use of health care and in
admissions to hospital [1]. In a population-based study, women
had a 70% higher risk than men of being admitted to hospital for
asthma after controlling for asthma prevalence and smoking [2].
Gender differences in hospital admissions for asthma could relate
to differences in the disease severity, perception and management.
In a cross-sectional study from the European Network For
Understanding Mechanisms Of Severe Asthma (ENFUMOSA),
women were found to dominate the group of subjects with severe
asthma as compared to the patients whose asthma was controlled
by low doses of inhaled corticosteroids[3]. In a high-risk adult
asthmatic cohort, two thirds of admissions were women, suggesting
that women might suffer from a more severe form of asthma [4].
Women also report more dyspnoea [5].
In a population-based prospective cohort with a 25-year follow-
up [6], women were more likely than men to have severe asthma
(OR: 1.57[1.19–2.08])), especially if asthma had developed after
the age of 2 years and was associated with reduced PEF.(Peak
Expiratory Flow).
In a cross-sectional survey, asthma severity increased with BMI
(Body Mass Index)only in women [7]. In a retrospective analysis, it
has been suggested that late-onset asthma, which generally occurs
during or after puberty, affects mainly women, and has a poor
prognosis[8]. In an unselected birth cohort, female sex predicted
persistence of asthma. In addition, lung function in males in whom
asthma relapsed after remission closely resembled that in males
with persistent asthma, whereas females with a relapse had
worsened lung function only as adults[9]. To our knowledge, no
longitudinal population-based study has investigated gender
difference in asthma severity.
The purpose of this study was to examine whether the evolution
of asthma severity was different in women and in men in a
longitudinal population-based survey.
Methods
Study design
The methods of the survey have been fully described
elsewhere[10,11]. Briefly, at the baseline survey (ECRHS I), 48
centers in 22 countries randomly selected around 3000 men and
3000 women aged 20 to 44 year-old who completed a short postal
questionnaire about asthma and asthma-like symptoms (stage 1).
From 1991 to 1993, a 20% random subsample of responders were
invited to attend a local test center (stage 2) to complete a more
detailed questionnaire administered by an interviewer and to
undergo skin prick and blood tests, assessment of lung function by
spirometry, and airway challenge with methacholine. The
selection of these subjects was ideally made by random selection
from a suitable sampling frame. The aim was to obtain 300 of each
gender. In addition, participants who were not in the random
sample, but who reported that they had at least one asthma-like
symptom (symptomatic sample) or were currently taking medicine
for asthma, were also invited to participate in stage 2. Participants
gave written informed consent, and institutional or regional ethics
committee approved the study in each participating center.
All participants to ECRHS I stage2 were eligible for
participating in the follow-up survey (ECRHS II, n=14 countries)
during 1998–2002. The same protocol was used for the follow-up
survey, including an administered clinical interview, lung function
measurements, and serum IgE samples.
Twenty-seven centers participated in ECRHS II. The full
protocol can be found at www.ecrhs.org.
Definition of asthma
Participants were defined as having current asthma if they
answered positively to the question ‘‘have you ever had asthma’’
and if they had had at least one asthma attack in the last 12
months or were ‘‘currently taking any medicines including
inhalers, aerosols or tablets for asthma’’. Subjects with current
asthma at the baseline survey, but without current asthma at the
follow-up survey were considered to be in remission at follow-up.
Subjects who had no history of asthma in ECRHS-I and who had
current asthma in ECRHS-II were considered to be incident
asthmatics.
Only asthmatics whose respiratory function met the American
Thoracic Society (ATS) criterion for reproducibility [12]were
included in the study.
Evaluation of asthma severity
Asthma severity was first classified as intermittent, mild
persistent, moderate persistent, or severe persistent using the
GINA guidelines[13] that were available at the time of ECRHS-I.
Two independent GINA classifications were combined as
recommended for the description of asthma severity in a
population [14]one based on symptoms and FEV1 and called
‘‘Clinical Step’’ (Step C 1–4); and the other based on current
medication and called ‘‘treatment step’’ (Step T 1–4) to construct a
final ‘‘symptom-FEV1 medication’’ classification.
N GINA classification1992
Four levels of severity were considered for each of the ‘‘Clinical’’
and ‘‘Treatment’’ classifications (step)
Clinical step (Step C)
Step C1 (Intermittent): Asthma attacks less than once a week
and FEV1$80% predicted. The patients not classified as
step 1 were assigned to the other steps as follows.
Step C2 (Mild persistent): all patients not allocated to the other
steps, with a FEV1.=80% predicted.
Step C3 (Moderate persistent): Patients with 60%, FEV1,80%
predicted, or daily attacks
Step C4 (Severe persistent): All patients with FEV1,=60%
predicted.
Treatment step (Step T) (defined according to current
asthma medication)
Step T1: No controller medication or only short-agonist
bronchodilator.
Step T2: Inhaled corticosteroids or theophylline without oral
corticosteroids
Step T3: Inhaled corticosteroids and theophylline or long-acting
bronchodilator but without oral corticosteroids.
Step T 4: Oral corticosteroids.
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highest step between the ‘‘clinical step’’ and ‘‘treatment step’’.
Subjects with asthma at ECRHS II were classified using the
same classification, as for ECRHS I. However we also classified
subjects with asthma at ECRHS II using a more detailed version
of GINA (2004) that also takes into account the nocturnal
symptoms, and the dose of inhaled steroids
– GINA guidelines 2004[15] were applied to the second
survey and then compared with the 1992 guidelines in order to
evaluate the agreement between the two classifications. The
main differences were the presence of nocturnal symptoms for
clinical step and inhaled corticosteroids for treatment step. This
information was not available in the first survey.
Again, two independent GINA classifications were combined:
one based only on symptoms and FEV1 and called ‘‘clinical step’’
(Step C 1–4); and the other based on current medication to
construct a final ‘‘symptom-FEV1 medication’’ classification and
called ‘‘treatment step’’ (Step T 1–4). Each step was divided into
four levels of severity.
Clinical step
Step C 1 (Intermittent): symptoms less than once a week and
nocturnal symptoms not more than twice a month and
FEV1.=80% predicted. The patients not classified as step 1
were assigned to the other steps as follows.
Step C 4 (Severe persistent): FEV1,=60% predicted.
StepC 3 (Moderate persistent): Patients with 60%, FEV1,80%
predicted, and daily symptoms or night-time asthma .1/week.
Step C 2 (Mild persistent): all patients not allocated to the other
steps, with a FEV1.=80% predicted.
Treatment step according to current asthma medication
Stept T1: No controller medication, or only short-agonist
bronchodilator.
Stept T4: Oral corticosteroids or inhaled corticosteroids
.2,000 ug/day
Stept T2: Inhaled corticosteroids ,=500 ug/day without oral
corticosteroids
Stept T3: Inhaled corticosteroids ,=1000 ug/day and long-
acting bronchodilator but without oral corticosteroids.
The final severity step was based on the two independent
classifications of clinical step and treatment step, according to the
GINA, as previously mentioned.
Ronchetti Score. Secondly, asthma was classified as
intermittent, mild persistent, moderate persistent, severe
persistent by using a second approach based on a score derived
from Ronchetti et al.[16], and previously used in the same
population[17]. This score was based on
– FEV1 (forced expiratory volume in one second) (mild.80%,
moderate 70–80%, severe ,70%),
– number of asthma attacks in the previous 12 months (2, 3–6,
.6)
– number of admissions to hospital for breathing problems in the
previous 12 months (0, 1–2, .2)
– wether inhaled or oral corticosteroids had been taken in the
past 12 months.
Each of the first three variables had three levels of increasing
severity (scored 1, 2 or 3) and the fourth variable had two levels
(scored 1 or 2). The overall total score therefore ranged from 4 to
11, with levels of severity being intermittent (score 4 or 5, without
inhaled corticosteroids), mild persistent (score 4 or 5, with inhaled
corticosteroids), moderate persistent (score=6) and severe persis-
tent (score.=7).
This classification was applied using the same algorithm at the
two study periods.
Statistical analysis
The associations between the different levels of severity of
asthma and categorial variables were assessed with the test in the
SAS-PC statistical package (SAS Institute, Cary, NC). The Kappa
test was used to compare one classification used for severity versus
another classification. 0.7 shoud be consider as a good concor-
dance; 0.8–1 to an excellent concordance. Comparisons were
done using synthesis of each classification.
Secondly, we performed logistic regressions to assess the odds
ratio for the associations between risk factors and moderate-severe
asthma versus intermittent-mild asthma, taking potential con-
founders into account, and geographic centers included in the
model as an additional explanatory variable. Risk factors were
selected among risk factors usually published in the literature,
mainly age, sensitization to cat allergen, house dust mite, and
molds, smoking habits. The logistic regression was a stepwise
approach. Alpha risk was 5%.
Results
All current asthmatics identified in ECRHS I and who
participated in ECRHS II were eligible for this analysis. Of the
17579 participants examined at stage 2, 1485 currently had
asthma in ECRHS-I. Of those, 1091 could be classified for asthma
severity at Ec1 (missing data: 35 for FEV1, 46 had FEV1 value
without ATS conformity, 181 for the number of asthma attacks,
178 for both admissions and asthma treatment) (figure 1).
In men (n=481):
– 183 were lost to follow-up at Ec2
– 150 were in remission at Ec2
– 148 were still asthmatic at Ec2
In women (n=610):
– 194 were lost to follow-up at Ec2
– 215 were in remission at Ec2
– 201 were still asthmatic at Ec2
Comparison between participants and subjects lost to follow-up
are shown in table 1. The mean follow-up was 8.65 yr (min 4.3-
max 11.7). There were significantly more females and smokers in
the second sample. Moreover, there was no significant difference
according to FEV1%pred, atopy or severity of asthma. Stratifi-
cation by gender in men and women demonstrated a high
prevalence of smokers in the sample ‘‘lost to follow-up’’ (table 1).
According to the 1992 GINA classification, 40.7% of asthmatics
at baseline were classified intermittent, 31.7% as mild persistent,
14% as moderate persistent, and 13.5% as severe persistent. The
comparison of men and women in EC1 by GINA (p=0.04) is
weak (table 2).
Using the Ronchetti score derived classification, the distribution
of asthma severity was 58% mild, (intermittent and mild
persistent), 25.8% moderate, and 15.4% severe.
Whatever the classification used, the distribution of asthma
severity at baseline was not different in men and in women. At
Evolution of Asthma Severity
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severity.
In subjects included in the second survey (n=685, both followed
and incident), the concordance of the two classifications was
compared (GINA 1992 vs GINA 2004) at follow-up. The Kappa
coefficient was 0.48 [0.20–0.58].
In contrast, gender differences were observed in the evolution of
severity. Figure 2 shows the distribution of asthma severity
between at follow-up, in incident asthmatics who had no asthma
at the first survey, and in cases with asthma at baseline taking into
account the severity of asthma at baseline.
There was no gender difference for severity in incident
asthmatics. Using the Ronchetti score, the proportion of incident
cases classified as having ‘‘mild’’ asthma was 62% in men and 69%
in women (p=0.7). There was also no gender difference in the
distribution of asthma severity according to GINA for patients
with incident asthma.
Using the Ronchetti classification (Fig. 2A), around 80% of
subjects with mild asthma at baseline still had mild asthma, or had
no ‘‘current asthma’’ at follow-up. According to both classifica-
tions, men with moderate-to-severe asthma at EC-1 were more
likely than women to have moderate-to-severe asthma at EC-2:
using Ronchetti-score, 53.3% of men vs. 36.2% of women with
moderate-to-severe asthma at EC-1 were still moderate-to-severe
at EC-2, (p=0.03).
Using the GINA classification (Fig. 2B), 69.2% of men vs.
53.1% of women, with moderate-to-severe asthma at EC-1 were
still moderate-to-severe at EC-2, (p=0.09).
In contrast, in asthmatics with intermittent asthma at EC-1, the
likelihood to develop moderate-to-severe asthma at EC-2 was
higher in women (16.3% using GINA) than in men (8.8%),
although the difference was not significant (p=0.15). Using
Ronchetti score, the likelihood to develop moderate-to-severe
asthma at EC-2 was higher in women (20%) than in men (14.5%)
(NS).
As regards hospitalization, respectively, 18%, and 22% of
subjects with moderate persistent asthma, and severe persistent
asthma were hospitalized for asthma during the previous year,
without any significant difference between men and women.
As regards symptoms and lung function of subjects with severe
asthma, 19.3% of women reported .12 asthma attacks in the
preceding year or had FEV1,60% (‘‘poor asthma control’’) versus
30.2% of men. Conversely, 52.7% of men versus 37.1% of women
with severe asthma were receiving a treatment that was ‘‘lower’’
than the one recommended for their level of severity.
Finally, in order to identify the factors related to change in
asthma severity, we analyzed the subsample of subjects with
moderate-to-severe asthma in the first survey (n=127) and
separated them into two groups: those who still had moderate-
to-severe asthma in the second survey and those whose severity
improved whatever the classification used, forty-seven subjects had
an unchanged severity while 19 subjects were changed.
In women with moderate-to-severe asthma at baseline,
sensitization to cat was associated with a higher risk of having
no improvement in asthma severity at the second follow-up (59.3%
vs 33%; p=0.04). In contrast, in men three main factors were
associated with no change in asthma severity: age at the second
survey (more than 45 years) (52.8% vs 26%; OR: 0.76[0.59–0.98]
p=0.04), smoking history (66.6% vs 30.4%, OR: 0.85 [0.68–0.90]
p=0.006), and sensitization to molds (41.6% vs 9%; OR:
0.6[0.55–0.85] p=0.008).
Discussion
This investigation using two approaches is the first to study the
evolution of asthma severity in a population-based longitudinal
cohort of men and women. Whatever the classification, there was
no difference in the overall distribution of asthma severity between
men and women. However, investigating change in severity over
time suggested that asthma severity might be more stable in men
than in women. In particular, 69.2% of men with moderate-to-
severe asthma at baseline still had moderate-to-severe asthma after
a median follow-up of 8.7 years, whereas only 53.1% of women
with moderate-to-severe asthma remained moderate-to-severe. In
men with moderate-to severe asthma, factors significantly
associated with the risk of remaining at the same level of severity
were age, smoking status, and sensitization to mold. In women
with moderate-to-severe asthma, only sensitization to cat was
associated with no improvement in asthma severity at follow-up.
Various factors have been suggested to explain gender
differences in asthma prevalence and incidence such as hormonal
modulation[5], gender difference in hyper reactivity [18,19,20],
preferential exposure of women to environmental triggers such as
aeroallergens, and ventilatory response to PcO2[4].
However, it is unclear whether men or women generally suffer
worse symptoms and greater deficits in lung function. Prevalence
of asthma and allergies had been mapped by several international
Figure 1. Study design.
doi:10.1371/journal.pone.0007146.g001
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of asthma severity in the general population from an epidemio-
logic point of view.
Assessment of severity is one of several keys to asthma
management. Guidelines and consensus statements have been
formulated by international panels of experts with regard to degree
of severity and treatment[13,15]. Asthma is characterized by
various clinical symptoms such as episodic breathlessness,
wheezing and chest tightness, with seasonal variability. According
to the guidelines, severity may be judged by measurements of
symptoms, lung function, and medication requirements. However,
medication use might not be fully adequate for accurate severity
classification, because it depends both on the practitioner and
adherence to treatment by the patient, with the concomitant risk
of under- or over-treatment. In addition, doses of inhaled
corticosteroids may be subject to recall bias. Other factors,
including comorbidity medical conditions that mimic asthma such
as vocal cord dysfunction, may also lead to potential misclassifi-
cation of patients with severe asthma [22].
Assessment of asthma severity in cohort studies has been mainly
based on respiratory function [9]. Several studies have attempted
to define severity scores using different approaches in children[16]
and in adults[14]. Liard et al. proposed a classification using
GINA guidelines [14] in a population of asthmatics recruited by
chest physicians. By contrast, other authors included emergency
visits or hospitalizations in severity assessment [16,17]. Emergency
visits and hospitalizations are usually used to describe the impact
of the disease, which is related to asthma morbidity. It has been
shown that acute asthma exacerbation is often life-threatening in
patients who attend accident and emergency departments because
of inadequate treatment, mainly due to under use of corticoste-
roids and inappropriate admission rates according to exacerbation
severity[23]. However, including hospitalizations in the assessment
of asthma severity is still a subject of debate. Recently, in a selected
population of patients with difficult-to-treat asthma (TENOR),
Miller et al. compared asthma severity assessment according to
three methodologies[24]. They showed that classification of
asthma severity on the basis of current asthma symptoms and
lung function may be useful but not completely reflective of a
patient’s true asthma condition. Clinical assessment of asthma
severity should consider a patient’s medication use and consump-
tion of health care resources for asthma exacerbation. They
suggested that many adults with a history of moderate-to-severe
allergic asthma in childhood had irreversible lung function
deficits[25]. In addition, urgent care visits for asthma per year is
now included in the criteria for defining severe/refractory asthma
(20).
In our study, we found no gender difference in the overall
distribution of asthma severity in the cross-sectional analyses,
whatever the classification used. ‘‘In many studies investigating
severe asthma, women are found to dominate the severe asthma
group, with 59% to 82%(*) of severe asthmatics being women[22].
However, women also generally dominate the non-severe asthma
Table 1. Characteristics of subjects who provided respiratory data in the two assessments as compared with those not followed-
up at the second survey by gender.
Gender Men Men Women Women
Participants Lost to follow-up p Participants Lost to follow-up P
N=148 N=183 N=201 N=194
Age, m 33.3(7.2) 32.1(7.2) 0.36 34(7.2) 32.2(7.2) 0.36
Age of first asthma attack 14.3(11) 14(11.2) 0.23 19.3(11.7) 18.4(10.8) 0.13
Smoking, % 23.2 37.1 0.005 26.7 36 0.0037
%FEV1 pred 92.5(17.7) 91.7(18.7) 0.10 96.8(15.8) 94(17.2) 0.12
Atopy,% 66.3 68.9 0.56 58.2 61.3 0.48
Rhinitis,% 70.5 74.8 0.30 76 66.5 0.01
Severity,%
Intermittent 47.6 45.2 0.75 33.9 31.5 0.07
Mild P. 29.2 27.1 34.3 36.2
Moderate P. 11.9 10.5 16.1 15.3
Severe P. 11.3 11.2 15.8 14.7
Hospitalizations,% 19.8 20.9 0.77 19.9 22.7 0.43
Emergency visits,% 32 34 0.63 34.5 33. 0.71
doi:10.1371/journal.pone.0007146.t001
Table 2. Cross-sectional distribution of asthma severity in
subjects with data available at both surveys.
EC1 EC1 P EC2 EC2 P
‘‘Ronchetti’’ Men Women Men Women
Mild, % 56.9 60.5 0.38 59.1 64.7 0.26
Moderate, % 28.7 22.9 21.1 20.3
Severe, % 14.4 16.5 19.8 15
EC2 EC2 P EC2 EC2 P
‘‘GINA’’ Men Women Men Women
I, % 47.6 33.9 0.04 28.8 28.5 0.89
II, % 29.2 34.3 37.6 35.1
III, % 11.9 16.1 22.1 24.7
IV, % 11.3 15.8 11.5 11.7
*comparison of men and women in EC1 by GINA (p=0.04) is weak.
doi:10.1371/journal.pone.0007146.t002
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showing no difference in the overall distribution of asthma severity
between asthmatic men and asthmatic women [7]. In the
ENFUMOSA study, however, the male to female ratio was still
higher in the severe asthma group than in the group of asthmatics
whose asthma was controlled by low doses of inhaled corticoste-
roids (male to female ration: 4.4:1 vs. 1.6:1, respectively;
p,0.001)[3].
Differences in the procedure to identify and select asthmatic
cases, and differences in severity definitions may explain the
differences observed. In a recent study published by the TENOR
group, females reported significantly greater healthcare utilization
than males, significantly more asthma control problems and lower
asthma-related quality of life. Despite their overall worse health
outcomes, female subjects demonstrated better lung function, had
similar treatment patterns, and showed no differences in
physician-assessed asthma severity when compared with males
[26]. In our study, moderate-to-severe asthma was more
particularly characterized by a decrease in FEV1 (,60%pred) in
men whereas in women it was associated with more intensive
treatment. There was no significant difference between men and
women with regard to hospitalization increases with asthma
severity at the two surveys. These two results suggest that a
significant gender difference exists for severity of the disease and
for management (i.e. treatment). In our subjects, prevalence of
remission was 23%. Remission diminished whereas asthma
severity increased both in men and women. In the study by Sears
et al.[9], remission was defined as the absence of wheezing after
wheezing had been reported at two or more successive prior
assessments. As in our study, similar remission rates (around 15%)
were observed in men and in women. To our knowledge, little is
known about gender difference in remission according to level of
asthma severity.
Although no gender differences were observed in the overall
distribution of asthma severity, differences were observed in the
evolution of severity between the two surveys. In a cross-sectional
analysis of the subjects with asthma from the ECRHS dataset at
baseline, Zureik et al. showed that asthma severity was associated
with sensitization to airborne moulds[17]. An other cross-sectional
analysis showed that subjects with severe asthma at follow-up had
poorer FEV1% predicted at baseline, poorer symptom control,
higher IgE levels, and higher prevalence of chronic cough/mucus
hypersecretion than patients with intermittent asthma. This study
is the first to report on gender differences in changes in asthma
severity, taking into account severity at baseline. Women were not
more exposed to risk factors of change than men, suggesting that
Figure 2. Distribution of asthma severity at EC2 in subjects without current asthma at EC1 (ECI-0) and in subjects with asthma,
according to asthma severity at EC-1.
doi:10.1371/journal.pone.0007146.g002
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adulthood. However, another explanation could be that subjects
whose severity changed could have had poorly controlled asthma
at the first survey. Evaluation of asthma control is still difficult in
clinical practice and is difficult to evaluate in epidemiological
studies. Asthma is a complex, chronic disease varying from
minutes to years. Our findings suggest that evolution of asthma
severity is different in men and in women, and this difference is to
be taken into account when investigating the variability of asthma
severity in epidemiological studies.
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